We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with Good Manufacturing Practice (“GMP”) standards on a self-declared basis.
Partnerships Charité (Berlin Institute of Health): PROTO project (EU Horizon grant) for Phase I/II study in mild to moderate knee osteoarthritis; study approved by Paul-Ehrlich-Institut June 2025. Tel-Aviv Sourasky Medical Center (Ichilov): Phase I/II trial for steroid-refractory chronic GVHD (1% royalty on net sales, capped ~$500k)
Hematopoietic complications of acute radiation syndrome (H-ARS)(Preclinical)
Status note NIAID provided $1.4M to manufacture PLX-R18 and conduct in vitro/in vivo studies for H-ARS; contract terminated by NIAID for the government's convenience effective April 15, 2025.
Status note Novel allogeneic immunotherapy platform launched May 2024; designed as universal product with low GvHD risk and enhanced tumor homing.
Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.